Topic: Alzheimer's disease

This Keystone Symposium integrates fundamental mechanisms, precision diagnostics, and therapeutic development for Alzheimer's disease, non-Alzheimer dementias, and other neurodegenerative disorders. Joint programming with the Neural-Immune Interactions meeting connects disease mechanisms and clinical strategy with immune modulation of central nervous system biology.

The MIT Aging Brain Initiative brings together work in molecular imaging, cognition, chemistry, bioengineering, neurodegeneration, and artificial intelligence to address brain aging and Alzheimer's prevention.

Develop antibody-based approaches to Alzheimer’s disease at the Queensland Brain Institute. The project investigates tau-targeting monoclonal antibodies through protein production, cell-based experiments and mouse studies. Responsibilities include analysing results, preparing publications, contributing to funding applications and supporting junior researchers. This full-time appointment runs for up to 12 months, with an immediate start preferred. Annual base pay is AUD 85,373–113,660, plus 17% superannuation.

Bryce Mander presents research on early sleep biomarkers associated with Alzheimer's disease pathophysiology and memory impairment. The William C. Dement Seminar connects sleep and circadian neuroscience with neurodegeneration, cognition and clinically relevant approaches to detecting disease-related change.

Parallel Squared Technology Institute is recruiting research associate and senior research associate candidates to operate and maintain mass spectrometers, prepare protein samples, manage reagents and samples, and analyze experimental data. The institute is developing high-throughput protein-analysis technology with initial applications in Alzheimer’s disease and aging.

Ai2 is recruiting a postdoctoral Young Investigator for CellOLMo, a collaboration using open language models with single-cell brain data. The researcher will develop multimodal models that combine gene-expression data and text, evaluate biological language grounding on the SEA-AD Alzheimer's disease atlas, build donor- and brain-region-level representations, and release resulting models, code, data, and research artifacts openly.

Parallel Squared Technology Institute is recruiting scientist and senior-scientist candidates to use single-cell proteomics to investigate protein dysfunction in Alzheimer's disease and related neurodegenerative conditions. The work spans human brain tissue, molecular mechanisms, single-cell analysis, and computational biology in an interdisciplinary team.